close
References
  1. Eapen M, Rocha V, Sanz G, et al; Center for International Blood and Marrow Transplant Research; Acute Leukemia Working Party Eurocord (the European Group for Blood Marrow Transplantation); National Cord Blood Program of the New York Blood Center. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol. 2010;11(7):653-660.
  2. Gale RP, Eapen M. Who is the best alternative allotransplant donor? Bone Marrow Transplant. 2015;50(suppl 2):S40-42.
  3. Ruggeri A. Optimizing cord blood selection. Hematology Am Soc Hematol Educ Program. 2019;1:522-531.
  4. Versluis J, Labopin M, Ruggeri A, et al. Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1. Blood Adv. 2017;1(7):477-485.
  5. Sharma P, Purev E, Haverkos B, et al. Adult cord blood transplant results in comparable overall survival and improved GRFS vs matched related transplant. Blood Adv. 2020;4(10):2227-2235.
  6. Milano F, Gooley T, Wood B, et al. Cord-blood transplantation in patients with minimal residual disease. N Engl J Med. 2016;375(10):944-953.
  7. Sanz J, Veys P, Rocha V. Umbilical cord blood transplantation in children and adults. In: Carreras E, Dufour C, Mohty M, Kröger N, eds. The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies [internet]. 7th ed. Springer; 2019: Chapter 64. www.ncbi.nlm.nih.gov/books/NBK554021/ doi: 10.1007/978-3-030-02278-5_64. Accessed March 9, 2021.
  8. Dehn J, Spellman S, Hurley CK, et al. Selection of unrelated donors and cord blood units for hematopoietic cell transplantation: guidelines from the NMDP/CIBMTR. Blood. 2019;134(12):924-934.
  9. Garcia JG, Grillo S, Cao Q, et al. Low 5-year health care burden after umbilical cord blood transplantation. Blood Adv. 2021;5(3):853-860.
  10. Fuchs EJ, O'Donnell PV, Eapen M, et al. Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial. Blood. 2021;137(3):420-428.
  11. Barker JN, Weisdorf DJ, DeFor TE, et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood. 2005;105(3):1343-1347.
  12. Brunstein CG, Gutman JA, Weisdorf DJ, et al. Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. Blood. 2010;116(22):4693-4699.
  13. Gupta AO, Wagner JE. Umbilical cord blood transplants: current status and evolving therapies. Front Pediatr. 2020;8:570282.
  14. Kindwall-Keller TL, Ballen KK. Umbilical cord blood: the promise and the uncertainty. Stem Cells Transl Med. 2020;9(10):1153-1162.
  15. Horwitz ME, Chao NJ, Rizzieri DA, et al. Umbilical cord blood expansion with nicotinamide provides long-term multilineage engraftment. J Clin Invest. 2014;124(7):3121-3128.
  16. Horwitz ME, Wease S, Blackwell B, et al. Phase I/II study of stem-cell transplantation using a single cord blood unit expanded ex vivo with nicotinamide. J Clin Oncol. 2019;37(5):367-374.
  17. Horwitz ME, Stiff P, Rezvani AR, et al. Improved clinical outcomes with omidubicel versus standard myeloablative umbilical cord blood transplantation: results of a phase III randomized, multicenter study. Slides presented at: 2021 Transplantation and Cellular Therapy Meetings; February 8-12, 2021; Virtual.